Facebook Twitter YouTube Google Plus

P.) Mesothelioma Tissue Bank

Michael Becich, MD, PhD
University of Pittsburgh Medical Center

Dr. Michael Becich is Professor and Chairman of the Department of Biomedical Informatics at the University of Pittsburgh School of Medicine. He is jointly appointed in Pathology, Information Sciences/Telecommunications and Clinical/Translational Research. He is Associate Director of the University of Pittsburgh Cancer Institute and Co-Director of the Clinical and Translational Science Institute at the University of Pittsburgh School of Medicine. Dr. Becich's research interests are focused on the interface between clinical informatics and bioinformatics. His research is funded by the NCI, NCRR, NLM, NIDCR, CDC, TATRC and the DOD and includes clinical phenotyping of patients for genome wide association studies, tissue banking informatics and bioinformatics with a special emphasis on data sharing.


Click here to view the slides for "Mesothelioma Tissue Bank", by Michael Becich, MD.

To view this video, please click on the image below.

© 2009 Mesothelioma Applied Research Foundation, Inc. All rights reserved. 501(c)(3)

A.) Effective Advocacy and the Case for Federal Meso Research Funding

B.) State Assistance on Insurance Appeals

C.) Cancer Genetics in the Mesothelioma Family

D.) Fundraising

E.) Navigating Mesothelioma Clinical Trials with GPS (Getting Personalized Service)

F.) Update from Across the Pond

G.) The Mesothelioma Experience: Patient and Provider Perspectives Panel

H.) Work of the Science Advisory Board

J.) Present and Future of Mesothelioma Treatment: Medical Oncologist and Researcher Perspective

K.) New Developments in Radiation Oncology: A Global Perspective

M.) Pain Management

Mesothelioma Treatment: Present & Future from a Surgeon & Research Perspective | Dr. Harvey Pass

N.) Traditional Healing with Modern Science

O.) Update on Clinical Trials and Mesothelioma Research

P.) Mesothelioma Tissue Bank

Photodynamic Therapy for Mesothelioma Treatment | Dr. Joseph Friedberg

Q.) EGFR Inhibitors for Patients with Malignant Peritoneal Mesothelioma

R.) The Use of Cytokine Inhibitors: Translational Lab Results

S.) Identifying and Targeting Aggressive Malignant Peritoneal Mesothelioma: Morphologic and Molecular Studies

T.) Treatment Options for Patients with Recurrent Disease after HIPEC, HRA - Panel Discussion